S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

Catalyst Pharmaceuticals (CPRX) SEC Filings & 10K Form

$16.00
+0.46 (+2.96%)
(As of 04/17/2024 ET)

Recent Catalyst Pharmaceuticals SEC Filings

DateFilerForm TypeView
04/10/2024
4:15 PM
Catalyst Pharmaceuticals (Issuer)
Tierney David S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/10/2024
3:23 PM
Catalyst Pharmaceuticals (Filer)
Form DEF 14A
04/10/2024
3:25 PM
Catalyst Pharmaceuticals (Filer)
Form ARS
04/08/2024
1:03 PM
Catalyst Pharmaceuticals (Subject)
Tierney David S (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/28/2024
3:45 PM
Catalyst Pharmaceuticals (Issuer)
Elsbernd Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2024
2:01 PM
Catalyst Pharmaceuticals (Subject)
Elsbernd Brian (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/13/2024
4:01 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/28/2024
4:16 PM
Catalyst Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/12/2024
4:31 PM
Catalyst Pharmaceuticals (Subject)
Flynn James E (Filed by)
Form SC 13G/A
02/06/2024
4:00 PM
Catalyst Pharmaceuticals (Issuer)
DENKHAUS DONALD A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/31/2024
4:01 PM
Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/25/2024
9:09 AM
Catalyst Pharmaceuticals (Subject)
STATE STREET CORP (Filed by)
Form SC 13G/A
01/09/2024
4:15 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2024
7:10 AM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/05/2024
4:23 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/05/2024
4:15 PM
Catalyst Pharmaceuticals (Filer)
Form 424B5
01/03/2024
4:18 PM
Catalyst Pharmaceuticals (Issuer)
Kalb Michael Wayne (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
01/03/2024
4:18 PM
Catalyst Pharmaceuticals (Issuer)
Daly Richard J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2024
4:18 PM
Catalyst Pharmaceuticals (Issuer)
O'Keeffe Charles B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2024
4:19 PM
Catalyst Pharmaceuticals (Issuer)
Tierney David S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2024
4:19 PM
Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
DENKHAUS DONALD A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Miller Steve (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
GRANDE ALICIA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
INGENITO GARY (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Daly Richard J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Del Carmen Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Tierney David S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Harper Molly (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Sundaram Preethi (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
O'Keeffe Charles B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Elsbernd Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Harper Molly (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2023
3:30 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/15/2023
12:47 PM
Catalyst Pharmaceuticals (Subject)
Harper Molly (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/12/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Del Carmen Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Thompson Tamar (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Harper Molly (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Sundaram Preethi (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
MCENANY PATRICK J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Forget Nvidia, buy this A.I. Stock Now (Ad)

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.
12/12/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
DENKHAUS DONALD A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Elsbernd Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
GRANDE ALICIA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
O'Keeffe Charles B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Miller Steve (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Tierney David S (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
INGENITO GARY (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
1:21 PM
Catalyst Pharmaceuticals (Subject)
Tierney David S (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2023
1:57 PM
Catalyst Pharmaceuticals (Subject)
GRANDE ALICIA (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2023
11:54 AM
Catalyst Pharmaceuticals (Subject)
GRANDE ALICIA (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/08/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
INGENITO GARY (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2023
3:31 PM
Catalyst Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
12/08/2023
3:31 PM
Catalyst Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
12/07/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Miller Steve (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/07/2023
3:30 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/06/2023
11:48 AM
Catalyst Pharmaceuticals (Subject)
INGENITO GARY (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/05/2023
3:46 PM
Catalyst Pharmaceuticals (Subject)
Catalyst Pharmaceuticals (Subject)
Miller Steve (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/03/2023
3:30 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/27/2023
3:30 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/20/2023
3:31 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/13/2023
7:15 AM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/25/2023
3:31 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/21/2023
3:30 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/17/2023
3:30 PM
Catalyst Pharmaceuticals (Filer)
Form ARS
07/12/2023
3:31 PM
Catalyst Pharmaceuticals (Filer)
Form DEF 14A
06/29/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Del Carmen Jeffrey (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/23/2023
3:31 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2023
4:00 PM
Catalyst Pharmaceuticals (Issuer)
Thompson Tamar (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
05/30/2023
3:32 PM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/10/2023
3:07 PM
Catalyst Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/09/2023
7:43 AM
Catalyst Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/24/2023
3:30 PM
Catalyst Pharmaceuticals (Filer)
Form 10-K/A
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:CPRX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners